Akihito Watanabe
Research Subjects
Akihito Watanabe has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Masanobu Taniguchi
Department of Otolaryngology Keiyukai Sapporo Hospital Hondori 9 cho‐me Minami 1‐1, Shiroishi‐ku Sapporo Hokkaido 003‐0026 Japan
20 shared publicationsHitoshi Tsujie
10 shared publicationsMasao Hosokawa
Department of Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan
9 shared publicationsShigeyuki Sasaki
Division of Medical Science, Health Sciences University of Hokkaido, Ishikari-tobetsu, Japan
7 shared publicationsYuki Kimura
Department of Otolaryngology Keiyukai Sapporo Hospital Hondori 9 cho‐me Minami 1‐1, Shiroishi‐ku Sapporo Hokkaido 003‐0026 Japan
5 shared publicationsMasahiro Fujita
4 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by AVES YAYINCILIK A.Ş. in Balkan ORL-HNS
- Vol. 3 (1) , 1-10
Multidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes
Background: Lenvatinib demonstrates efficacy in radioiodine-refractory differentiated thyroid cancer (RR-DTC), but managing adverse events (AEs) remains challenging. This study evaluated real-world outcomes of lenvatinib therapy supervised by a multidisciplinary team without dedicated medical oncologists. Methods: The study retrospectively analyzed 44 DTC patients treated with lenvatinib (June 2015–December 2023), divided into long-term (≥657 days, n = 22) and short-term (<657 days, n = 22) groups based on median treatment duration. Results: The long-term group showed significantly superior objective response rate (95.5% vs. 27.3%, P < .001), overall survival, and progression-free survival. Grade 3 fatigue occurred more frequently in the short-term group (45.5% vs. 9.1%, P = .016), with earlier onset (47.0 vs. 206.5 days, P = .022), representing the leading cause of AE-related treatment discontinuation. The long-term group more frequently implemented planned drug holidays (40.9% vs. 13.6%) and dose escalation (63.6% vs. 18.2%, P = .005), which were associated with prolonged treatment continuation. Multidisciplinary management, including pharmacist-led monitoring and telephone consultations, facilitated early detection and appropriate management of AEs. Conclusions: Early identification and proactive management of fatigue, the most critical treatment-limiting adverse event, were essential for sustaining long-term lenvatinib therapy in real-world practice. Multidisciplinary care provided a supportive framework for fatigue-oriented management, enabling prolonged treatment in regional healthcare settings without dedicated medical oncology specialists. Cite this article as: Demachi T, Watanabe A, Kimura Y, et al. Multidisciplinary team management of lenvatinib therapy in differentiated thyroid cancer: real-world long-term treatment outcomes. Balkan ORL-HNS, 2026, 3, 0133, doi: 10.5152/bohns.2026.25133.
- 27 February 2026
- Published by AVES YAYINCILIK A.Ş. in Balkan ORL-HNS
- Vol. 3 (1) , 1-10
Open AccessMultidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes
Background: Lenvatinib demonstrates efficacy in radioiodine-refractory differentiated thyroid cancer (RR-DTC), but managing adverse events (AEs) remains challenging. This study evaluated real-world outcomes of lenvatinib therapy supervised by a multidisciplinary team without dedicated medical oncologists. Methods: The study retrospectively analyzed 44 DTC patients treated with lenvatinib (June 2015–December 2023), divided into long-term (≥657 days, n = 22) and short-term (<657 days, n = 22) groups based on median treatment duration. Results: The long-term group showed significantly superior objective response rate (95.5% vs. 27.3%, P < .001), overall survival, and progression-free survival. Grade 3 fatigue occurred more frequently in the short-term group (45.5% vs. 9.1%, P = .016), with earlier onset (47.0 vs. 206.5 days, P = .022), representing the leading cause of AE-related treatment discontinuation. The long-term group more frequently implemented planned drug holidays (40.9% vs. 13.6%) and dose escalation (63.6% vs. 18.2%, P = .005), which were associated with prolonged treatment continuation. Multidisciplinary management, including pharmacist-led monitoring and telephone consultations, facilitated early detection and appropriate management of AEs. Conclusions: Early identification and proactive management of fatigue, the most critical treatment-limiting adverse event, were essential for sustaining long-term lenvatinib therapy in real-world practice. Multidisciplinary care provided a supportive framework for fatigue-oriented management, enabling prolonged treatment in regional healthcare settings without dedicated medical oncology specialists. Cite this article as: Demachi T, Watanabe A, Kimura Y, et al. Multidisciplinary team management of lenvatinib therapy in differentiated thyroid cancer: real-world long-term treatment outcomes. Balkan ORL-HNS, 2026, 3, 0133, doi: 10.5152/bohns.2026.25133.
- 20 March 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (7) , 1773-1779
Artificial Nerve Conduit for Recurrent Laryngeal Nerve Reconstruction in Thyroid Surgery
Objective Oncological reconstruction of the recurrent laryngeal nerve (RLN) is sometimes necessary for RLN invaded by thyroid cancer. There have been no case reports of RLN reconstruction using artificial nerve conduits, which are often used for peripheral nerves. In this study, we retrospectively evaluate the feasibility, safety, and efficacy of a collagen conduit with collagen filaments for RLN reconstruction cases at our hospital.Methods Artificial nerve conduits were used in seven cases of RLN reconstruction. Two patients had preoperative unilateral vocal cord paralysis with severe vocal cord atrophy, and two had vocal cord paresis without atrophy. The remaining three patients had functional vocal cords before surgery that had to be resected via surgery due to thyroid cancer infiltration of the RLN. Reconstruction was performed using RENERVE (R), which is a collagen conduit. Voice examination and laryngeal endoscopy were performed 1, 3, and 12 months after surgery.Results There was no improvement in the phonetics of the two patients with vocal cord atrophy before surgery. In the remaining five cases, three with functional vocal cords improved to preoperative values, and two with vocal cord paresis improved to greater than preoperative values.Conclusion We report the first case series using an artificial nerve conduit for human RLN reconstruction. In cases of RLN resection when the patient has good voice quality pre-operatively, reconstruction of the RLN using an artificial nerve may be a favorable option in cases where direct anastomosis or ansa cervicalis to RLN anastomosis cannot be performed.
- 20 March 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (7) , 1773-1779
Artificial Nerve Conduit for Recurrent Laryngeal Nerve Reconstruction in Thyroid Surgery
Objective Oncological reconstruction of the recurrent laryngeal nerve (RLN) is sometimes necessary for RLN invaded by thyroid cancer. There have been no case reports of RLN reconstruction using artificial nerve conduits, which are often used for peripheral nerves. In this study, we retrospectively evaluate the feasibility, safety, and efficacy of a collagen conduit with collagen filaments for RLN reconstruction cases at our hospital.Methods Artificial nerve conduits were used in seven cases of RLN reconstruction. Two patients had preoperative unilateral vocal cord paralysis with severe vocal cord atrophy, and two had vocal cord paresis without atrophy. The remaining three patients had functional vocal cords before surgery that had to be resected via surgery due to thyroid cancer infiltration of the RLN. Reconstruction was performed using RENERVE (R), which is a collagen conduit. Voice examination and laryngeal endoscopy were performed 1, 3, and 12 months after surgery.Results There was no improvement in the phonetics of the two patients with vocal cord atrophy before surgery. In the remaining five cases, three with functional vocal cords improved to preoperative values, and two with vocal cord paresis improved to greater than preoperative values.Conclusion We report the first case series using an artificial nerve conduit for human RLN reconstruction. In cases of RLN resection when the patient has good voice quality pre-operatively, reconstruction of the RLN using an artificial nerve may be a favorable option in cases where direct anastomosis or ansa cervicalis to RLN anastomosis cannot be performed.
- 21 September 2021
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 42 (10) , 1232-1238
Evaluation of the risk of metachronous multiple squamous cell carcinoma of the head and neck after transoral surgery based on the genetic polymorphisms of alcohol dehydrogenase 1B and aldehyde dehydrogenase 2
Patients with superficial head and neck squamous cell carcinoma (HNSCC) can be completely treated by techniques of transoral surgery (TOS). The aim of this study was to evaluate the risk of metachronous multiple HNSCC arising after TOS based on alcohol dehydrogenase 1B (ADH1B) and aldehyde dehydrogenase 2 (ALDH2). We registered patients who underwent TOS for superficial HNSCC. Buccal cell samples were obtained by using a cotton swab to examine two single nucleotide polymorphisms in ADH1B and ALDH2 genotyping. We used Cox proportional hazards models to examine the risk of metachronous HNSCC. A total of 198 patients who underwent TOS for HNSCC were evaluated. In multivariate analysis, risks for second HNSCC were ADH1B*1/*1 [hazard ratio (HR), 1.88; 95% confidence interval (CI), 1.11–3.19; P = 0.02], ALDH2*1/*2 (HR, 2.11; 95% CI, 1.00–5.16; P = 0.048) and alcohol consumption before TOS (HR, 1.17; 95% CI, 1.06–1.27; P = 0.01). The 5-year incidence rates of second primary HNSCC in the temperance group and the non-temperance group were 20.8 and 46.5%, respectively (HR, 0.54; 95% CI, 0.31–0.92; P = 0.02). Cumulative development rates of third HNSCC in the temperance group and non-temperance group at 10 years were 11.3 and 36.1%, respectively (HR, 0.19; 95% CI, 0.03–0.65; P = 0.006). ADH1B*1/*1, ALDH2*1/*2 and moderate or heavy alcohol consumption before treatment are independent risk factors of metachronous HNSCC. Since it was shown that temperance decreased the incidences of second and third metachronous HNSCC, advice to discontinue alcohol drinking is necessary.
- 21 September 2021
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 42 (10) , 1232-1238
Evaluation of the risk of metachronous multiple squamous cell carcinoma of the head and neck after transoral surgery based on the genetic polymorphisms of alcohol dehydrogenase 1B and aldehyde dehydrogenase 2
Patients with superficial head and neck squamous cell carcinoma (HNSCC) can be completely treated by techniques of transoral surgery (TOS). The aim of this study was to evaluate the risk of metachronous multiple HNSCC arising after TOS based on alcohol dehydrogenase 1B (ADH1B) and aldehyde dehydrogenase 2 (ALDH2). We registered patients who underwent TOS for superficial HNSCC. Buccal cell samples were obtained by using a cotton swab to examine two single nucleotide polymorphisms in ADH1B and ALDH2 genotyping. We used Cox proportional hazards models to examine the risk of metachronous HNSCC. A total of 198 patients who underwent TOS for HNSCC were evaluated. In multivariate analysis, risks for second HNSCC were ADH1B*1/*1 [hazard ratio (HR), 1.88; 95% confidence interval (CI), 1.11–3.19; P = 0.02], ALDH2*1/*2 (HR, 2.11; 95% CI, 1.00–5.16; P = 0.048) and alcohol consumption before TOS (HR, 1.17; 95% CI, 1.06–1.27; P = 0.01). The 5-year incidence rates of second primary HNSCC in the temperance group and the non-temperance group were 20.8 and 46.5%, respectively (HR, 0.54; 95% CI, 0.31–0.92; P = 0.02). Cumulative development rates of third HNSCC in the temperance group and non-temperance group at 10 years were 11.3 and 36.1%, respectively (HR, 0.19; 95% CI, 0.03–0.65; P = 0.006). ADH1B*1/*1, ALDH2*1/*2 and moderate or heavy alcohol consumption before treatment are independent risk factors of metachronous HNSCC. Since it was shown that temperance decreased the incidences of second and third metachronous HNSCC, advice to discontinue alcohol drinking is necessary.
- 17 March 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (9) , 2036-2040
Evaluation of Pharyngeal Background Mucosa in Patients with Superficial Hypopharyngeal Carcinoma
Objectives/Hypothesis: Transoral surgery (TOS) has become increasingly popular for patients with superficial hypopharyngeal squamous cell carcinoma (SCC). However, the number of patients in whom metachronous multiple SCC of the head and neck (HNSCC) occurs has also increased. In this study, we investigated whether multiple lugol‐voiding lesions (LVLs) in the pharyngeal background mucosa observed during TOS would be a biomarker of metachronous HNSCC.Study Design: Retrospective study.Methods: We examined 362 patients who underwent TOS for superficial hypopharyngeal carcinoma. Endoscopic images were reviewed in a blinded fashion by two endoscopists. LVLs in the pharyngeal mucosa were graded as follows: A, no lesions; B, 1 to 4 lesions; and C, ≥5 lesions per endoscopic view.Results: Cumulative incidence curves of secondary HNSCC in the groups of grades A, B, and C revealed 3‐year incidence rates of 14.4%, 18.8%, and 29.3%, respectively (P = .001 for A vs. C and P = .002 for B vs. C). Cumulative incidence curves of third HNSCC in the groups of grades A, B. and C revealed 5‐year incidence rates of 3.9%, 9.8%, and 19.6%, respectively (P = .001 for A vs. C and P = .006 for B vs. C). Cumulative incidence curves of fourth HNSCC in the groups of grades A, B, and C revealed 7‐year incidence rates of 0%, 2.3%, and 13.2%, respectively (P = .025 for A vs. C and P = .009 for B vs. C).Conclusions: Multiple LVLs in the pharyngeal mucosa increase the risk of development of metachronous multiple HNSCC.Level of Evidence: 3 (nonrandomized, controlled cohort/follow‐up study) Laryngoscope, 131:2036–2040, 2021
- 17 March 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (9) , 2036-2040
Evaluation of Pharyngeal Background Mucosa in Patients with Superficial Hypopharyngeal Carcinoma
Objectives/Hypothesis: Transoral surgery (TOS) has become increasingly popular for patients with superficial hypopharyngeal squamous cell carcinoma (SCC). However, the number of patients in whom metachronous multiple SCC of the head and neck (HNSCC) occurs has also increased. In this study, we investigated whether multiple lugol‐voiding lesions (LVLs) in the pharyngeal background mucosa observed during TOS would be a biomarker of metachronous HNSCC.Study Design: Retrospective study.Methods: We examined 362 patients who underwent TOS for superficial hypopharyngeal carcinoma. Endoscopic images were reviewed in a blinded fashion by two endoscopists. LVLs in the pharyngeal mucosa were graded as follows: A, no lesions; B, 1 to 4 lesions; and C, ≥5 lesions per endoscopic view.Results: Cumulative incidence curves of secondary HNSCC in the groups of grades A, B, and C revealed 3‐year incidence rates of 14.4%, 18.8%, and 29.3%, respectively (P = .001 for A vs. C and P = .002 for B vs. C). Cumulative incidence curves of third HNSCC in the groups of grades A, B. and C revealed 5‐year incidence rates of 3.9%, 9.8%, and 19.6%, respectively (P = .001 for A vs. C and P = .006 for B vs. C). Cumulative incidence curves of fourth HNSCC in the groups of grades A, B, and C revealed 7‐year incidence rates of 0%, 2.3%, and 13.2%, respectively (P = .025 for A vs. C and P = .009 for B vs. C).Conclusions: Multiple LVLs in the pharyngeal mucosa increase the risk of development of metachronous multiple HNSCC.Level of Evidence: 3 (nonrandomized, controlled cohort/follow‐up study) Laryngoscope, 131:2036–2040, 2021
- 30 April 2020
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 33 (12)
Larynx-preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery for cervical esophageal cancer invading pharynx
Summary: Larynx preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery (HELPS) was created for resectable cervical esophageal cancer (CEC) invading the hypopharynx. This study aimed to verify the effectiveness and to evaluate the feasibility of the new HELPS treatment method. Between 2014 and 2018, 19 patients with CEC invading the hypopharynx were treated with HELPS. The postoperative complications and survival rates were reviewed. Postoperative recurrent laryngeal nerve paralysis occurred in four patients. All patients consumed food orally without a feeding tube at the time of the discharge. The median follow-up period was 27 months. The 2- and 3-year overall survival rates were 94.7 and 71.5%, respectively. HELPS, a new surgical treatment method that utilizes endoscopic surgery, is effective, feasible and beneficial for preserving the larynx in patients with CEC even if the tumor invaded the pharynx.
- 30 April 2020
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 33 (12)
Larynx-preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery for cervical esophageal cancer invading pharynx
Summary: Larynx preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery (HELPS) was created for resectable cervical esophageal cancer (CEC) invading the hypopharynx. This study aimed to verify the effectiveness and to evaluate the feasibility of the new HELPS treatment method. Between 2014 and 2018, 19 patients with CEC invading the hypopharynx were treated with HELPS. The postoperative complications and survival rates were reviewed. Postoperative recurrent laryngeal nerve paralysis occurred in four patients. All patients consumed food orally without a feeding tube at the time of the discharge. The median follow-up period was 27 months. The 2- and 3-year overall survival rates were 94.7 and 71.5%, respectively. HELPS, a new surgical treatment method that utilizes endoscopic surgery, is effective, feasible and beneficial for preserving the larynx in patients with CEC even if the tumor invaded the pharynx.
- 29 June 2017
- Published by Wiley in Head & Neck
- Vol. 39 (9) , 1779-1787
Synopsis of transoral endoscopic laryngopharyngeal surgery for superficial pharyngeal cancers
Endoscopic laryngopharyngeal surgery (ELPS) was developed for superficial pharyngeal cancers in Japan. In this study, we present our results of ELPS for superficial pharyngeal cancers. From November 2009 to December 2015, 258 patients with superficial pharyngeal cancers underwent ELPS. Results, including survival rates, postoperative complications, and vocal function, are reviewed. The median follow-up period of 258 patients was 31 months. The overall and cause-specific survival rates over 3 years were 85.7% and 100%, respectively. Only 3 patients incurred local recurrences and were successfully salvaged by re-ELPS. Regarding postoperative complications, 4 patients required reoperation because of postoperative bleeding. As for the postoperative quality of life, no patients developed vocal fold paralysis. Every patient was able to consume meals at preoperative levels. ELPS is a feasible and minimally invasive treatment for superficial pharyngeal cancers with impressive quality of life results.
- 29 June 2017
- Published by Wiley in Head & Neck
- Vol. 39 (9) , 1779-1787
Synopsis of transoral endoscopic laryngopharyngeal surgery for superficial pharyngeal cancers
Endoscopic laryngopharyngeal surgery (ELPS) was developed for superficial pharyngeal cancers in Japan. In this study, we present our results of ELPS for superficial pharyngeal cancers. From November 2009 to December 2015, 258 patients with superficial pharyngeal cancers underwent ELPS. Results, including survival rates, postoperative complications, and vocal function, are reviewed. The median follow-up period of 258 patients was 31 months. The overall and cause-specific survival rates over 3 years were 85.7% and 100%, respectively. Only 3 patients incurred local recurrences and were successfully salvaged by re-ELPS. Regarding postoperative complications, 4 patients required reoperation because of postoperative bleeding. As for the postoperative quality of life, no patients developed vocal fold paralysis. Every patient was able to consume meals at preoperative levels. ELPS is a feasible and minimally invasive treatment for superficial pharyngeal cancers with impressive quality of life results.
- Open Access
- 9 December 2014
- Published by Wiley in Head & Neck
- Vol. 38 (4) , 573-577
Efficient, effective, safe procedure to identify nonrecurrent inferior laryngeal nerve during thyroid surgery
Background The nonrecurrent inferior laryngeal nerve (NRILN) is always associated with the aberrant subclavian artery. CT images can detect this vascular anomaly, which predicts an NRILN. The purpose of this study was to report our procedure to identify the NRILN in patients with the aberrant subclavian artery. Methods Four of 730 patients undergoing thyroid operation in our hospital were preoperatively diagnosed with aberrant subclavian artery by CT of the neck. To avoid vocal cord paralysis, we approached the vagal nerve first before dissecting the paratracheal region to discover the separation point of the NRILN from the vagal nerve. Results The NRILN was identified without difficulty in all 4 patients. No patients showed vocal cord paralysis. Conclusion Approaching the vagal nerve first before dissecting the paratracheal region is an efficient, effective, and safe procedure to identify an NRILN in patients who are preoperatively diagnosed as having the aberrant subclavian artery. © 2015 Wiley Periodicals, Inc. Head Neck 38: 573–577, 2016
- 9 December 2014
- Published by Wiley in Head & Neck
- Vol. 38 (4) , 573-577
Open AccessEfficient, effective, safe procedure to identify nonrecurrent inferior laryngeal nerve during thyroid surgery
Background The nonrecurrent inferior laryngeal nerve (NRILN) is always associated with the aberrant subclavian artery. CT images can detect this vascular anomaly, which predicts an NRILN. The purpose of this study was to report our procedure to identify the NRILN in patients with the aberrant subclavian artery. Methods Four of 730 patients undergoing thyroid operation in our hospital were preoperatively diagnosed with aberrant subclavian artery by CT of the neck. To avoid vocal cord paralysis, we approached the vagal nerve first before dissecting the paratracheal region to discover the separation point of the NRILN from the vagal nerve. Results The NRILN was identified without difficulty in all 4 patients. No patients showed vocal cord paralysis. Conclusion Approaching the vagal nerve first before dissecting the paratracheal region is an efficient, effective, and safe procedure to identify an NRILN in patients who are preoperatively diagnosed as having the aberrant subclavian artery. © 2015 Wiley Periodicals, Inc. Head Neck 38: 573–577, 2016
- 1 April 2012
- Published by Elsevier in Auris Nasus Larynx
- Vol. 39 (2) , 193-197
Clinical impact of iodine staining for diagnosis of carcinoma in situ in the floor of mouth, and decision of adequate surgical margin
- 1 April 2012
- Published by Elsevier in Auris Nasus Larynx
- Vol. 39 (2) , 193-197
Clinical impact of iodine staining for diagnosis of carcinoma in situ in the floor of mouth, and decision of adequate surgical margin